The national budget impact of managed entry agreement strategies match with high-cost drugs to maximise drug cost saving: a study protocol
Background Drug expenditure is an important part of health expenditure. Managed Entry Agreement (MEA) is a common strategy implemented in many countries, such as the United States, the United Kingdom, and the European countries to control drug expenditures, especially for new and high-cost drugs. Th...
Saved in:
Main Authors: | Piyapat Owat (Author), Chaoncin Sooksriwong (Author), Hataiwan Ratanabunjerdkul (Author), Tuangrat Phodha (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical trials and drug cost savings for Italian health service
by: Francesca D'Ambrosio, et al.
Published: (2020) -
The effective and innovative cost saving of software in managing unregistered drugs
by: Nur Wahida Zulkifli, et al.
Published: (2015) -
Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis.
by: Aastha Gupta, et al.
Published: (2022) -
Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis
by: Aastha Gupta, et al.
Published: (2022) -
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
by: Panos Kefalas, et al.
Published: (2018)